von Bargen, Maximilian Ferry
Glienke, M.
Tonyali, S.
Sigle, A.
Wilhelm, K.
Schoenthaler, M.
Gratzke, C.
Miernik, A. http://orcid.org/0000-0001-5894-9647
Funding for this research was provided by:
Universitätsklinikum Freiburg
Article History
Received: 7 May 2024
Accepted: 21 June 2024
First Online: 2 August 2024
Declarations
:
: This study was approved by the local ethics committee of Albert-Ludwigs-University of Freiburg, Germany (Approval number: 22-1465-S1-retro) as this was a retrospective study and all the procedures being performed were part of the routine care.
: Not applicable for this section due to retrospective nature of the study.
: Not applicable for this section.
: A. Miernik receives research funds of the German Federal Ministry of Education and Research, Berlin (D). He receives support for his travel activities from the European Society of Urology, Arnhem (NL), and the German Society of Urology, DĂĽsseldorf (D). Furthermore, (A) Miernik is consulted for: KLS Martin, Tuttlingen (D), Avateramedical, Jena (D), LISA Laser Products GmbH, Katlenburg-Lindau (D), Schoelly fiberoptics GmbH, Denzlingen (D), Dornier MedTech Systems GmbH (D), Medi-Tate Ltd. (IL, USA) and (B) Braun New Ventures GmbH, Freiburg (D). A. Miernik is speaker for the companies Richard Wolf GmbH (D) and Boston Scientific (USA). Additionally, he performed expert activities for the Ludwig Boltzmann Gesellschaft, Wien (A). A. Miernik is involved in numerous patents and inventions in the field of medical technology. Prof. Dr. Christian Gratzke is adviser for Astellas Pharma GmbH, DE, Ipsen Pharma GmbH, DE, Steba Biotech S.A., LUX, Bayer Pharma, DE, Olympus Winter & Ibe GmbH, DE, Medi-Tate Ltd., IL, MSD, DE, Astra-Zeneca, UK and Roche, CH. He receives speaker fees from Amgen, USA, Astellas Pharma GmbH, DE, Ipsen Pharma GmbH, DE, Janssen-Cilag GmbH, BEL, Bayer Pharma, DE, Takeda Pharmaceuticals, JPN and medac GmbH, DE. M. von Bargen, M. Glienke, S. Tonyali, A. Sigle, K. Wilhelm, and M. Schoenthaler declare to have no conflicts of interest.